Edit Reading

Back to List

Basic Information

Title

Please enter a title.

URL

Please enter a valid URL.

Date

カテゴリID

画像ファイル名

単語数（空欄の場合は本文から自動計算）空欄の場合は本文から自動計算されます。本文が空欄の場合は既存の値が保持されます。

統計情報

現在の単語数: 182語

読了回数: 0回

作成日: 2024/05/25 07:00

更新日: 2025/12/08 13:47

本文

An expert panel of Japan&#039;s health ministry has approved the expanded use of the anti-influenza drug, Avigan, to treat a tick-borne viral infection called severe fever with thrombocytopenia syndrome, or SFTS.
                
Once the ministry formally greenlights the medication, it will become the world&#039;s first therapeutic drug for SFTS.
                
Patients with SFTS mostly get the viral infection through tick bites. Symptoms include fever and diarrhea, but no effective medication is currently available.
                
The health ministry says up to 30 percent of SFTS cases in Japan have been fatal.
                
Avigan was developed by Fujifilm Toyama Chemical.
The company sought the health ministry&#039;s approval for the drug&#039;s use against SFTS last August, saying it had obtained data on its efficacy.
                
On Friday, the health ministry panel confirmed that the drug is effective and that there are no serious concerns over its safety.
                
Avigan was initially approved as an anti-flu drug in Japan in 2014, and is stockpiled by the government.
                
The drug cannot be used by expecting mothers or women who might be pregnant, as animal testing showed that it could cause deformities in fetuses.

メモ

メモ・感想

キャンセル

Edit Reading

Basic Information

統計情報

本文

メモ

Send Report